Leyre Urigüen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leyre Urigüen has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
- J. Javier Meana
University of the Basque Country
12 shared publications - Luis Felipe Callado
University of the Basque Country
11 shared publications - Rebeca Diez-Alarcia
Department of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Spain
10 shared publications - Jorge Manzanares
Instituto de Neurociencias, Universidad Miguel Hernández-CSIC, Avda. de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain
8 shared publications Paula Unzueta-Larrinaga
Department of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Spain
7 shared publications- Inés Ibarra-Lecue
Department of Pharmacology, University of the Basque Country UPV/EHU and Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM, Leioa, Spain
6 shared publications
Latest Publications
- Open Access
- 28 November 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (12) , 1817
Cannabinoids and Extracellular Vesicles as Potential Biomarkers and Therapeutic Targets in Neuropsychiatric Disorders: A Hypothesis-Driven Review
Background and Objectives: Neuropsychiatric disorders pose a major global health challenge, marked by high prevalence, limited diagnostic precision, and suboptimal therapeutic outcomes. Current diagnoses remain primarily clinical, lacking objective biomarkers, while many patients experience poor remission rates and frequent relapse. The endocannabinoid system (ECS), a central regulator of synaptic plasticity, neuroinflammation, and stress responses, is increasingly implicated in depression, anxiety, schizophrenia, and neurodegenerative diseases. In parallel, extracellular vesicles (EVs) have emerged as critical mediators of intercellular communication and promising biomarker sources, as they reflect the physiological or pathological status of their cells of origin. This review examines the hypothesis that interactions between ECS signaling and EV-mediated communication form a convergent pathway shaping vulnerability and resilience in neuropsychiatric disorders, with potential implications for biomarker identification and therapeutic innovation. Methods: This hypothesis-driven review was developed using a narrative approach, focusing on the interface between cannabinoids and EVs in neuropsychiatric conditions. Relevant publications were identified through PubMed, Scopus, and Web of Science searches up to September 2025. Results: Emerging evidence indicates a bidirectional relationship between ECS activity and EV biology: endocannabinoids can be loaded into EVs to facilitate intercellular signaling, while phytocannabinoids such as THC and CBD can alter EV release and cargo composition. Conclusions: We propose a hypothesis-driven framework in which the possible interplay between cannabinoids and EVs may stimulate new research and support the development of biomarker-guided, personalized therapeutic strategies for neuropsychiatric disorders.
- 28 November 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (12) , 1817
Open AccessCannabinoids and Extracellular Vesicles as Potential Biomarkers and Therapeutic Targets in Neuropsychiatric Disorders: A Hypothesis-Driven Review
Background and Objectives: Neuropsychiatric disorders pose a major global health challenge, marked by high prevalence, limited diagnostic precision, and suboptimal therapeutic outcomes. Current diagnoses remain primarily clinical, lacking objective biomarkers, while many patients experience poor remission rates and frequent relapse. The endocannabinoid system (ECS), a central regulator of synaptic plasticity, neuroinflammation, and stress responses, is increasingly implicated in depression, anxiety, schizophrenia, and neurodegenerative diseases. In parallel, extracellular vesicles (EVs) have emerged as critical mediators of intercellular communication and promising biomarker sources, as they reflect the physiological or pathological status of their cells of origin. This review examines the hypothesis that interactions between ECS signaling and EV-mediated communication form a convergent pathway shaping vulnerability and resilience in neuropsychiatric disorders, with potential implications for biomarker identification and therapeutic innovation. Methods: This hypothesis-driven review was developed using a narrative approach, focusing on the interface between cannabinoids and EVs in neuropsychiatric conditions. Relevant publications were identified through PubMed, Scopus, and Web of Science searches up to September 2025. Results: Emerging evidence indicates a bidirectional relationship between ECS activity and EV biology: endocannabinoids can be loaded into EVs to facilitate intercellular signaling, while phytocannabinoids such as THC and CBD can alter EV release and cargo composition. Conclusions: We propose a hypothesis-driven framework in which the possible interplay between cannabinoids and EVs may stimulate new research and support the development of biomarker-guided, personalized therapeutic strategies for neuropsychiatric disorders.
- Open Access
- 27 August 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (1) , 396-406
Extracellular matrix dysfunction and synaptic alterations in schizophrenia
Schizophrenia is a complex disorder with strong evidence implicating neurodevelopmental abnormalities in its pathophysiology. Olfactory neuroepithelial cells from patients provide a unique platform for studying neurodevelopmental processes. These cells can be cultured into neurospheres and differentiated into neurons, allowing the study of patient-specific alterations related to the disorder. In this study, we utilized olfactory neuroepithelial cells from patients with schizophrenia and controls to explore putative neurodevelopmental dysregulations. RNA-sequencing of neurospheres transcriptome revealed significant alterations in extracellular matrix-related gene expression, suggesting extracellular matrix dysregulation as an underlying contributor to schizophrenia etiopathogenesis. Upon differentiation of olfactory neuroepithelial cells into neurons, transcriptomic analysis identified a significant downregulation of genes involved in synaptic organization and extracellular matrix interactions. To validate these findings, we quantified the protein levels of these genes in olfactory neuroepithelium-derived neurons and in postmortem dorsolateral prefrontal cortex tissue from schizophrenia patients and matched controls. Consistent with our transcriptomic data, schizophrenia subjects exhibited decreased levels of L1CAM, SCG2, and NPTXR proteins. Furthermore, we identified a correlation between the protein levels of L1CAM and NPTXR in the brains of individuals with schizophrenia, a relationship that was absent in control subjects. Our findings provide robust evidence for extracellular matrix and synaptic dysregulation in schizophrenia, linking neurodevelopmental disruptions to molecular alterations in both patient-derived cellular models and postmortem brain. These results underscore the utility of olfactory neuroepithelium cells as a model for studying the neurodevelopmental basis of schizophrenia. They also highlight extracellular matrix-related pathways as potential targets for future search of biomarkers and therapeutic development.
- 27 August 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (1) , 396-406
Open AccessExtracellular matrix dysfunction and synaptic alterations in schizophrenia
Schizophrenia is a complex disorder with strong evidence implicating neurodevelopmental abnormalities in its pathophysiology. Olfactory neuroepithelial cells from patients provide a unique platform for studying neurodevelopmental processes. These cells can be cultured into neurospheres and differentiated into neurons, allowing the study of patient-specific alterations related to the disorder. In this study, we utilized olfactory neuroepithelial cells from patients with schizophrenia and controls to explore putative neurodevelopmental dysregulations. RNA-sequencing of neurospheres transcriptome revealed significant alterations in extracellular matrix-related gene expression, suggesting extracellular matrix dysregulation as an underlying contributor to schizophrenia etiopathogenesis. Upon differentiation of olfactory neuroepithelial cells into neurons, transcriptomic analysis identified a significant downregulation of genes involved in synaptic organization and extracellular matrix interactions. To validate these findings, we quantified the protein levels of these genes in olfactory neuroepithelium-derived neurons and in postmortem dorsolateral prefrontal cortex tissue from schizophrenia patients and matched controls. Consistent with our transcriptomic data, schizophrenia subjects exhibited decreased levels of L1CAM, SCG2, and NPTXR proteins. Furthermore, we identified a correlation between the protein levels of L1CAM and NPTXR in the brains of individuals with schizophrenia, a relationship that was absent in control subjects. Our findings provide robust evidence for extracellular matrix and synaptic dysregulation in schizophrenia, linking neurodevelopmental disruptions to molecular alterations in both patient-derived cellular models and postmortem brain. These results underscore the utility of olfactory neuroepithelium cells as a model for studying the neurodevelopmental basis of schizophrenia. They also highlight extracellular matrix-related pathways as potential targets for future search of biomarkers and therapeutic development.
- Open Access
- 23 January 2025
- Published by Springer Nature in Research Square
Extracellular Matrix Dysfunction Drives Synaptic Pathology in Schizophrenia
Schizophrenia is a complex disorder with strong evidence implicating neurodevelopmental abnormalities in its pathophysiology. Olfactory neuroepithelial cells from patients provide a unique platform for studying neurodevelopmental processes. These cells can be cultured into neurospheres and differentiated into neurons, allowing the study of patient-specific alterations related to the disorder. In this study, we utilized olfactory neuroepithelial cells from patients with schizophrenia and controls to explore putative neurodevelopmental dysregulations. RNA-sequencing of neurospheres transcriptome revealed significant alterations in extracellular matrix-related gene expression, suggesting extracellular matrix dysregulation as an underlying contributor to schizophrenia etiopathogenesis.Upon differentiation of olfactory neuroepithelial cells into neurons, transcriptomic analysis identified a significant downregulation of genes involved in synaptic organization and extracellular matrix interactions. To validate these findings, we quantified the protein levels of these genes in olfactory neuroepithelium-derived neurons and in postmortem dorsolateral prefrontal cortex tissue from schizophrenia patients and matched controls. Consistent with our transcriptomic data, schizophrenia subjects exhibited decreased levels of L1CAM, SCG2, and NPTXR proteins. Furthermore, we identified a correlation between the protein levels of L1CAM and NPTXR in the brains of individuals with schizophrenia, a relationship that was absent in control subjects. Our findings provide robust evidence for extracellular matrix and synaptic dysregulation in schizophrenia, linking neurodevelopmental disruptions to molecular alterations in both patient-derived cellular models and postmortem brain. These results underscore the utility of olfactory neuroepithelium cells as a model for studying the neurodevelopmental basis of schizophrenia. They also highlight extracellular matrix-related pathways as potential targets for future search of biomarkers and therapeutic development.
- 23 January 2025
- Published by Springer Nature in Research Square
Open AccessExtracellular Matrix Dysfunction Drives Synaptic Pathology in Schizophrenia
Schizophrenia is a complex disorder with strong evidence implicating neurodevelopmental abnormalities in its pathophysiology. Olfactory neuroepithelial cells from patients provide a unique platform for studying neurodevelopmental processes. These cells can be cultured into neurospheres and differentiated into neurons, allowing the study of patient-specific alterations related to the disorder. In this study, we utilized olfactory neuroepithelial cells from patients with schizophrenia and controls to explore putative neurodevelopmental dysregulations. RNA-sequencing of neurospheres transcriptome revealed significant alterations in extracellular matrix-related gene expression, suggesting extracellular matrix dysregulation as an underlying contributor to schizophrenia etiopathogenesis.Upon differentiation of olfactory neuroepithelial cells into neurons, transcriptomic analysis identified a significant downregulation of genes involved in synaptic organization and extracellular matrix interactions. To validate these findings, we quantified the protein levels of these genes in olfactory neuroepithelium-derived neurons and in postmortem dorsolateral prefrontal cortex tissue from schizophrenia patients and matched controls. Consistent with our transcriptomic data, schizophrenia subjects exhibited decreased levels of L1CAM, SCG2, and NPTXR proteins. Furthermore, we identified a correlation between the protein levels of L1CAM and NPTXR in the brains of individuals with schizophrenia, a relationship that was absent in control subjects. Our findings provide robust evidence for extracellular matrix and synaptic dysregulation in schizophrenia, linking neurodevelopmental disruptions to molecular alterations in both patient-derived cellular models and postmortem brain. These results underscore the utility of olfactory neuroepithelium cells as a model for studying the neurodevelopmental basis of schizophrenia. They also highlight extracellular matrix-related pathways as potential targets for future search of biomarkers and therapeutic development.
- Open Access
- 28 December 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-12
Uncovering metabolic dysregulation in schizophrenia and cannabis use disorder through untargeted plasma lipidomics
Cannabis use disorder affects up to 42% of individuals with schizophrenia, correlating with earlier onset, increased positive symptoms, and more frequent hospitalizations. This study employed an untargeted lipidomics approach to identify biomarkers in plasma samples from subjects with schizophrenia, cannabis use disorder, or both (dual diagnosis), aiming to elucidate the metabolic underpinnings of cannabis abuse and schizophrenia development. The use of liquid chromatography-high resolution mass spectrometry enabled the annotation of 119 metabolites, with the highest identification confidence level achieved for 16 compounds. Notably, a marked reduction in acylcarnitines, including octanoylcarnitine and decanoylcarnitine, was observed across all patient groups compared to controls. In cannabis use disorder patients, N-acyl amino acids (NAAAs), particularly N-palmitoyl threonine and N-palmitoyl serine, showed a strong downregulation, a pattern also seen in schizophrenia and dual diagnosis patients. Conversely, elevated levels of 7-dehydrodesmosterol were detected in schizophrenia and dual diagnosis patients relative to controls. These findings suggest a potential link between metabolic disruptions and the pathophysiology of both disorders. The untargeted lipidomics approach offers a powerful tool to identify novel biomarkers, enhancing our understanding of the biological relationship between cannabis abuse and schizophrenia, and paving the way for future therapeutic strategies targeting metabolic pathways in these conditions.
- 28 December 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-12
Open AccessUncovering metabolic dysregulation in schizophrenia and cannabis use disorder through untargeted plasma lipidomics
Cannabis use disorder affects up to 42% of individuals with schizophrenia, correlating with earlier onset, increased positive symptoms, and more frequent hospitalizations. This study employed an untargeted lipidomics approach to identify biomarkers in plasma samples from subjects with schizophrenia, cannabis use disorder, or both (dual diagnosis), aiming to elucidate the metabolic underpinnings of cannabis abuse and schizophrenia development. The use of liquid chromatography-high resolution mass spectrometry enabled the annotation of 119 metabolites, with the highest identification confidence level achieved for 16 compounds. Notably, a marked reduction in acylcarnitines, including octanoylcarnitine and decanoylcarnitine, was observed across all patient groups compared to controls. In cannabis use disorder patients, N-acyl amino acids (NAAAs), particularly N-palmitoyl threonine and N-palmitoyl serine, showed a strong downregulation, a pattern also seen in schizophrenia and dual diagnosis patients. Conversely, elevated levels of 7-dehydrodesmosterol were detected in schizophrenia and dual diagnosis patients relative to controls. These findings suggest a potential link between metabolic disruptions and the pathophysiology of both disorders. The untargeted lipidomics approach offers a powerful tool to identify novel biomarkers, enhancing our understanding of the biological relationship between cannabis abuse and schizophrenia, and paving the way for future therapeutic strategies targeting metabolic pathways in these conditions.
- Open Access
- 21 March 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (4) , 755-783
The CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls
Cereblon/CRBN is a substrate-recognition component of the Cullin4A-DDB1-Roc1 E3 ubiquitin ligase complex. Destabilizing mutations in the human CRBN gene cause a form of autosomal recessive non-syndromic intellectual disability (ARNSID) that is modelled by knocking-out the mouse Crbn gene. A reduction in excitatory neurotransmission has been proposed as an underlying mechanism of the disease. However, the precise factors eliciting this impairment remain mostly unknown. Here we report that CRBN molecules selectively located on glutamatergic neurons are necessary for proper memory function. Combining various in vivo approaches, we show that the cannabinoid CB 1 receptor (CB 1 R), a key suppressor of synaptic transmission, is overactivated in CRBN deficiency-linked ARNSID mouse models, and that the memory deficits observed in these animals can be rescued by acute CB 1 R-selective pharmacological antagonism. Molecular studies demonstrated that CRBN interacts physically with CB 1 R and impairs the CB 1 R-G i/o -cAMP-PKA pathway in a ubiquitin ligase-independent manner. Taken together, these findings unveil that CB 1 R overactivation is a driving mechanism of CRBN deficiency-linked ARNSID and anticipate that the antagonism of CB 1 R could constitute a new therapy for this orphan disease.
- 21 March 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (4) , 755-783
Open AccessThe CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls
Cereblon/CRBN is a substrate-recognition component of the Cullin4A-DDB1-Roc1 E3 ubiquitin ligase complex. Destabilizing mutations in the human CRBN gene cause a form of autosomal recessive non-syndromic intellectual disability (ARNSID) that is modelled by knocking-out the mouse Crbn gene. A reduction in excitatory neurotransmission has been proposed as an underlying mechanism of the disease. However, the precise factors eliciting this impairment remain mostly unknown. Here we report that CRBN molecules selectively located on glutamatergic neurons are necessary for proper memory function. Combining various in vivo approaches, we show that the cannabinoid CB 1 receptor (CB 1 R), a key suppressor of synaptic transmission, is overactivated in CRBN deficiency-linked ARNSID mouse models, and that the memory deficits observed in these animals can be rescued by acute CB 1 R-selective pharmacological antagonism. Molecular studies demonstrated that CRBN interacts physically with CB 1 R and impairs the CB 1 R-G i/o -cAMP-PKA pathway in a ubiquitin ligase-independent manner. Taken together, these findings unveil that CB 1 R overactivation is a driving mechanism of CRBN deficiency-linked ARNSID and anticipate that the antagonism of CB 1 R could constitute a new therapy for this orphan disease.
- Open Access
- 23 November 2023
- Published by Springer Nature in Research Square
Differential Serum Metabolomic Profile in Patients with Schizophrenia, Cannabis Use Disorder or Dual diagnosis
Cannabis use disorder occurs in up to 42% of subjects with schizophrenia. It has been associated with a lower age of onset of schizophrenia, more positive symptoms and a higher frequency of hospitalizations. A number of metabolomic-based studies have shown that levels of several amino acids and lipids are altered in plasma of schizophrenia patients. Similarly, different levels of various lipids, amino acids, sugars, proteins and other metabolites have been quantified in plasma of cannabis consumers, suggesting that consumption of cannabis does interfere in the regulation of further metabolic pathways. In the present study, we performed a non-targeted metabolomic approach in plasma samples of subjects with a diagnosis of schizophrenia, cannabis use disorder or dual diagnosis. The aim was to find potential biomarkers of the diseases and to gain a better understanding of the relation between cannabis abuse and the development of schizophrenia. The liquid chromatography-high resolution mass spectrometry outcomes allowed the annotation of 121 metabolites. The analysis between each group and the corresponding control samples showed a clearer clustering of the samples. The two-way ANOVA and linear analysis of the whole dataset showed that most of the analytes were differently present between the groups, but none of them seems to correlate to gender or age. It can be highlighted the presence of two endocannabinoids (palmitylethanolamide (PEA) and oleoylethanolamide (OEA)), nicotine and cotinine as biomarkers of tobacco consumption, and nor-9- carboxy-Δ9-THC as biomarker of the consumption of cannabis. Moreover, some medium chain acylcarnitines (C8/C10) share a common pattern in the three comparison groups whereas some N-acyl serines were also highlighted in some of the group comparisons. The use of this non-targeted metabolomic approach provided us a deep insight to evaluate the metabolomics profile and to uncover putative biomarkers in schizophrenia and cannabis use disorder.
- 23 November 2023
- Published by Springer Nature in Research Square
Open AccessDifferential Serum Metabolomic Profile in Patients with Schizophrenia, Cannabis Use Disorder or Dual diagnosis
Cannabis use disorder occurs in up to 42% of subjects with schizophrenia. It has been associated with a lower age of onset of schizophrenia, more positive symptoms and a higher frequency of hospitalizations. A number of metabolomic-based studies have shown that levels of several amino acids and lipids are altered in plasma of schizophrenia patients. Similarly, different levels of various lipids, amino acids, sugars, proteins and other metabolites have been quantified in plasma of cannabis consumers, suggesting that consumption of cannabis does interfere in the regulation of further metabolic pathways. In the present study, we performed a non-targeted metabolomic approach in plasma samples of subjects with a diagnosis of schizophrenia, cannabis use disorder or dual diagnosis. The aim was to find potential biomarkers of the diseases and to gain a better understanding of the relation between cannabis abuse and the development of schizophrenia. The liquid chromatography-high resolution mass spectrometry outcomes allowed the annotation of 121 metabolites. The analysis between each group and the corresponding control samples showed a clearer clustering of the samples. The two-way ANOVA and linear analysis of the whole dataset showed that most of the analytes were differently present between the groups, but none of them seems to correlate to gender or age. It can be highlighted the presence of two endocannabinoids (palmitylethanolamide (PEA) and oleoylethanolamide (OEA)), nicotine and cotinine as biomarkers of tobacco consumption, and nor-9- carboxy-Δ9-THC as biomarker of the consumption of cannabis. Moreover, some medium chain acylcarnitines (C8/C10) share a common pattern in the three comparison groups whereas some N-acyl serines were also highlighted in some of the group comparisons. The use of this non-targeted metabolomic approach provided us a deep insight to evaluate the metabolomics profile and to uncover putative biomarkers in schizophrenia and cannabis use disorder.
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S583-S584
DISCOVERING THE MOLECULAR MECHANISMS UNDERLYING CANNABIS-INDUCED INCREASED RISK OF SCHIZOPHRENIA: EVALUATION OF THE AKT/MTOR/S6 PATHWAY STATUS IN A DOUBLE HIT RODENT MODEL.
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S583-S584
Open AccessDISCOVERING THE MOLECULAR MECHANISMS UNDERLYING CANNABIS-INDUCED INCREASED RISK OF SCHIZOPHRENIA: EVALUATION OF THE AKT/MTOR/S6 PATHWAY STATUS IN A DOUBLE HIT RODENT MODEL.
- 19 July 2023
- Published by Springer Nature
- Vol. 2687, 57-64
Evaluation of Sensorimotor Gating Deficits in Mice Through Prepulse Inhibition (PPI) of the Startle Response
Prepulse inhibition of the startle response enables measuring animal behavior and helps us understand core aspects of neuropsychiatric diseases. Prepulse inhibition is considered a translational indicator of sensorimotor gating deficits present in schizophrenia patients and is crucial in the characterization of animal models of schizophrenia-like behaviors. Hallucinogenic drugs acting through 5-HT2A receptors, such as psilocybin, lysergic acid diethylamide (LSD), and dimethoxyiodoamphetamine (DOI), produce symptoms in healthy subjects comparable to those seen in schizophrenia and can be used in rodent models for mimicking some of these behaviors. Here we describe a protocol for the evaluation of prepulse inhibition of the startle response in CD1-Swiss male mice after a single dose of the hallucinogenic drug DOI. Key words Prepulse inhibition Animal models Psychiatric disorders DOI
- 19 July 2023
- Published by Springer Nature
- Vol. 2687, 57-64
Evaluation of Sensorimotor Gating Deficits in Mice Through Prepulse Inhibition (PPI) of the Startle Response
Prepulse inhibition of the startle response enables measuring animal behavior and helps us understand core aspects of neuropsychiatric diseases. Prepulse inhibition is considered a translational indicator of sensorimotor gating deficits present in schizophrenia patients and is crucial in the characterization of animal models of schizophrenia-like behaviors. Hallucinogenic drugs acting through 5-HT2A receptors, such as psilocybin, lysergic acid diethylamide (LSD), and dimethoxyiodoamphetamine (DOI), produce symptoms in healthy subjects comparable to those seen in schizophrenia and can be used in rodent models for mimicking some of these behaviors. Here we describe a protocol for the evaluation of prepulse inhibition of the startle response in CD1-Swiss male mice after a single dose of the hallucinogenic drug DOI. Key words Prepulse inhibition Animal models Psychiatric disorders DOI
- Open Access
- 28 April 2023
- Published by Springer Nature in Molecular Neurobiology
- Vol. 60 (8) , 4472-4487
Isolation and Differentiation of Neurons and Glial Cells from Olfactory Epithelium in Living Subjects
The study of psychiatric and neurological diseases requires the substrate in which the disorders occur, that is, the nervous tissue. Currently, several types of human bio-specimens are being used for research, including postmortem brains, cerebrospinal fluid, induced pluripotent stem (iPS) cells, and induced neuronal (iN) cells. However, these samples are far from providing a useful predictive, diagnostic, or prognostic biomarker. The olfactory epithelium is a region close to the brain that has received increased interest as a research tool for the study of brain mechanisms in complex neuropsychiatric and neurological diseases. The olfactory sensory neurons are replaced by neurogenesis throughout adult life from stem cells on the basement membrane. These stem cells are multipotent and can be propagated in neurospheres, proliferated in vitro and differentiated into multiple cell types including neurons and glia. For all these reasons, olfactory epithelium provides a unique resource for investigating neuronal molecular markers of neuropsychiatric and neurological diseases. Here, we describe the isolation and culture of human differentiated neurons and glial cells from olfactory epithelium of living subjects by an easy and non-invasive exfoliation method that may serve as a useful tool for the research in brain diseases.
- 28 April 2023
- Published by Springer Nature in Molecular Neurobiology
- Vol. 60 (8) , 4472-4487
Open AccessIsolation and Differentiation of Neurons and Glial Cells from Olfactory Epithelium in Living Subjects
The study of psychiatric and neurological diseases requires the substrate in which the disorders occur, that is, the nervous tissue. Currently, several types of human bio-specimens are being used for research, including postmortem brains, cerebrospinal fluid, induced pluripotent stem (iPS) cells, and induced neuronal (iN) cells. However, these samples are far from providing a useful predictive, diagnostic, or prognostic biomarker. The olfactory epithelium is a region close to the brain that has received increased interest as a research tool for the study of brain mechanisms in complex neuropsychiatric and neurological diseases. The olfactory sensory neurons are replaced by neurogenesis throughout adult life from stem cells on the basement membrane. These stem cells are multipotent and can be propagated in neurospheres, proliferated in vitro and differentiated into multiple cell types including neurons and glia. For all these reasons, olfactory epithelium provides a unique resource for investigating neuronal molecular markers of neuropsychiatric and neurological diseases. Here, we describe the isolation and culture of human differentiated neurons and glial cells from olfactory epithelium of living subjects by an easy and non-invasive exfoliation method that may serve as a useful tool for the research in brain diseases.
- Open Access
- 14 September 2022
- Published by Wiley in Addiction Biology
- Vol. 27 (6) , e13233
Cannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients
Cannabis use disorder is frequent in schizophrenia patients, and it is associated with an earlier age of onset and poor schizophrenia prognosis. Serotonin 2A receptors (5‐HT2AR) have been involved in psychosis and, like Akt kinase, are known to be modulated by THC. Likewise, endocannabinoid system dysregulation has been suggested in schizophrenia. The presence of these molecules in blood makes them interesting targets, as they can be evaluated in patients by a minimally invasive technique. The aim of the present study was to evaluate 5‐HT2AR protein expression and the Akt functional status in platelet homogenates of subjects diagnosed with schizophrenia, cannabis use disorder, or both conditions, compared with age‐ and sex‐matched control subjects. Additionally, endocannabinoids and pro‐inflammatory interleukin‐6 (IL‐6) levels were also measured in the plasma of these subjects. Results showed that both platelet 5‐HT2AR and the active phospho (Ser473)Akt protein expression were significantly increased in schizophrenia subjects, whereas patients with a dual diagnosis of schizophrenia and cannabis use disorder did not show significant changes. Similarly, plasma concentrations of anandamide and other lipid mediators such as PEA and DEA, as well as the pro‐inflammatory IL‐6, were significantly increased in schizophrenia, but not in dual subjects. Results demonstrate that schizophrenia subjects show different circulating markers pattern depending on the associated diagnosis of cannabis use disorder, supporting the hypothesis that there could be different underlying mechanisms that may explain clinical differences among these groups. Moreover, they provide the first preliminary evidence of peripherally measurable molecules of interest for bigger prospective studies in these subpopulations.
- 14 September 2022
- Published by Wiley in Addiction Biology
- Vol. 27 (6) , e13233
Open AccessCannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients
Cannabis use disorder is frequent in schizophrenia patients, and it is associated with an earlier age of onset and poor schizophrenia prognosis. Serotonin 2A receptors (5‐HT2AR) have been involved in psychosis and, like Akt kinase, are known to be modulated by THC. Likewise, endocannabinoid system dysregulation has been suggested in schizophrenia. The presence of these molecules in blood makes them interesting targets, as they can be evaluated in patients by a minimally invasive technique. The aim of the present study was to evaluate 5‐HT2AR protein expression and the Akt functional status in platelet homogenates of subjects diagnosed with schizophrenia, cannabis use disorder, or both conditions, compared with age‐ and sex‐matched control subjects. Additionally, endocannabinoids and pro‐inflammatory interleukin‐6 (IL‐6) levels were also measured in the plasma of these subjects. Results showed that both platelet 5‐HT2AR and the active phospho (Ser473)Akt protein expression were significantly increased in schizophrenia subjects, whereas patients with a dual diagnosis of schizophrenia and cannabis use disorder did not show significant changes. Similarly, plasma concentrations of anandamide and other lipid mediators such as PEA and DEA, as well as the pro‐inflammatory IL‐6, were significantly increased in schizophrenia, but not in dual subjects. Results demonstrate that schizophrenia subjects show different circulating markers pattern depending on the associated diagnosis of cannabis use disorder, supporting the hypothesis that there could be different underlying mechanisms that may explain clinical differences among these groups. Moreover, they provide the first preliminary evidence of peripherally measurable molecules of interest for bigger prospective studies in these subpopulations.